3 protocol(s) meet the specified criteria
Drug: Azacitidine
Protocol No.TitleStatus
BAML16-001-M1BAML16-001 (BEAT)_Phase 1/2 Umbrella Study-A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)Open
J1651Phase 2 Study of Azacitidine (AZA) in Combination with Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (>65 Years) AML PatientsOpen
PEVONEDISTAT-3001Pevonedistat-3001 A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous LeukemiaOpen